Tricida — Corporate Update (December 2020)
16 slides from Tricida's corporate update, Dec 8, 2020
Slide 1: Investor Presentation – Year-End Business Update
Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation – Year-End Business Update December 8, 2020 Exhibit 99.1
Slide 2: Forward Looking Statements
2 Forward Looking Statements Any statements contained in this presentation or made during the accompanying oral presentation that are not statements of historical facts are forward-looking statements as defined under the Federal securities laws. Examples of such statements include our plans, beliefs
Slide 3: Executive Summary
3 Executive Summary • Tricida has amended the VALOR-CKD trial protocol to a group sequential design with two interim analyses for early stopping for efficacy and no unblinded interim analysis for sample size re-estimation • A Formal Dispute Resolution Request (FDRR) has been submitted with the FDA t
Slide 4: VALOR-CKD Confirmatory Outcome Trial Design
4 VALOR-CKD Confirmatory Outcome Trial Design The trial terminates when the independent blinded Clinical Endpoint Adjudication Committee (CEAC) has positively adjudicated 511 subjects with primary efficacy endpoint events Time-to-event trial to evaluate the efficacy and safety of veverimer in delayi
Slide 5: The VALOR-CKD Trial is Well Underway
5 The VALOR-CKD Trial is Well Underway • As of December 7, 2020, the VALOR-CKD trial has randomized 1,277 of 1,600 subjects with an average treatment duration of ~1 year and has accrued 50 of the 511 required subjects with positively adjudicated primary endpoint events (renal death, ESRD, and/or ≥ 4
Slide 6: Deep Understanding of the Surrogate Effect and Clinical Benefit
6 Tricida has a Deep Understanding of the Surrogate Effect and How It Reasonably Likely Translates to Clinical Benefit • Tricida focused the End-of-Review Type A meeting on the topic of whether the magnitude of treatment effect observed in TRCA-301/301E was reasonably likely to predict clinical bene
Slide 7: New Design Reflects Increased Confidence in Updated Sample Size Assumptions
7 New Design Reflects Increased Confidence in Updated Sample Size Assumptions Prior New Interim Analyses Unblinded sample size re- estimation with potential for increase up to 3,200 subjects Eliminated Early stopping for efficacy (50% and 75% of events) Early stopping for efficacy (150 and 250 event
Slide 8: Interim Analyses Are Planned for Early Stopping for Efficacy
8 Interim Analyses Are Planned for Early Stopping for Efficacy • Interim alpha spending approach: O'Brien-Fleming alpha spending function – Nominal one-sided alpha required for significance at • Interim 1: 0.00004; observed HR will need to be < 0.50 • Interim 2: 0.00151; observed HR will need to be
Slide 9: VALOR-CKD Primary Endpoint Event Tracking
9 VALOR-CKD Primary Endpoint Event Tracking Interim analysis 1: Anticipated 2H 2021 Interim analysis 2: Anticipated mid-2022 Final analysis: Anticipated 2024 * Data on event rates among 2197 control group patients in 29 CKD trial. Required baseline eGFR of 20 to 40 mL/min/1.73m2 Source: Inker et al.
Slide 10: Formal Dispute Resolution Request
Formal Dispute Resolution Request
Slide 11: Recent FDA Interactions
11 Recent FDA Interactions • The Complete Response Letter (CRL) indicated that FDA was seeking additional data from at least one additional adequate and well-controlled study demonstrating the efficacy of veverimer for the treatment of metabolic acidosis associated with CKD • In the CRL, the FDA exp
Slide 12: FDRR Submitted Focusing on Narrow Issue of Requisite Magnitude of Benefit
12 A Formal Dispute Resolution Request (FDRR) Has Been Submitted that Focuses on the Narrow Issue of Requisite Magnitude of Benefit • Addressing the issues in the CRL is not a worthwhile endeavor unless Tricida can reach agreement with the FDA that the already-demonstrated magnitude of serum bicarbo
Slide 13: FDRR Submission and Potential Scenarios
13 FDRR Submission and Potential Scenarios • FDRR was submitted to the FDA in December 2020 and confirmation of acceptance for consideration is pending • If accepted, the timing and next steps will be dependent upon the OND’s decision. Potential scenarios include: – If the FDRR is granted,* the Divi
Slide 14: New Veverimer Composition of Matter Patent Extends Coverage to 2038
14 • Six already issued Orange Book eligible patents provide patent protection until 2034 • Several pending patent applications United States • Three issued EPO patents providing patent protection until 2034 and a fourth issued patent providing protection until 2035 • Several pending EPO patent appl
Slide 15: Financial Guidance
15 Financial Guidance • Tricida currently has the financial resources to fund our operations into at least mid-2022, prior to modifying any of its material agreements • Cash, cash equivalents and investments at September 30, 2020 were ~$376 million – Tricida has $75 million principal amount of debt
Slide 16: Thank You
THANK YOU IRICIDA